The infertility drugs market attained a value of USD 3.92 Billion in 2025 driven by the rising cases of infertility among men and women across the 8 major markets. It is expected to grow at a CAGR of 5.90% in the forecast period of 2026-2035 and attain a market value of USD 6.95 Billion by 2035.
Base Year
Historical Period
Forecast Period
The rapid increase in infertility rates and expansion of the endocrine-active chemicals market provide momentum to support growth and increase the demand for fertility drugs and treatments. The infertility drugs market is growing in key regions of the world, due to increasing requirements for non-invasive fertility options.
The United States is expected to account for a major share in the infertility drugs market, owing to the high rates of infertility, steady research investments, and favorable healthcare system.
The market growth is impacted by the rising awareness of infertility-related issues, supported by the government and company-driven initiatives.
Compound Annual Growth Rate
5.9%
Value in USD Billion
2026-2035
*this image is indicative*
Infertility drugs help in managing and treating infertility issues in both males and females. It can help in stimulating ovulation in women and balancing hormone levels necessary for reproductive health. In males, it may increase sperm count. Clomiphene citrate gonadotropins aromatase inhibitors are amongst the most frequently used medications that help infertility.
Rising Cases of Infertility among Men and Women to Boost the Growth of the Industry
According to the World Health Organisation's 2023 report, 1 in 6 people across the world are expected to witness difficulties conceiving, highlighting the dire requirement of accessible yet quality fertility care. The rising prevalence of infertility-related diseases such as hormonal imbalances, endometriosis, and ovarian cysts is a key factor driving the demand for infertility drugs. In addition, fertility issues are further worsened by stress, obesity, and smoking.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
“Infertility Drugs Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Gender
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
The Gonadotrophins Segment Based on Drug Class Holds a Significant Share in the Market
The market is segmented by drug class into gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, and others. The gonadotrophins drug class is anticipated to be the dominant segment among these. The market share can be attributed to its ability to considerably increase pregnancy chances in women. Women are also learning more about the decreased side effects of gonadotrophins, which boosts the market value of this segment.
Market Segmentation Based on Gender
Based on gender, the market is segmented into male and female. Among these, the female segment is expected to lead the market, as a large range of drugs is available for addressing female infertility issues. These drugs may involve ovulation stimulators, hormone treatments, and follicle-stimulating agents. In assisted reproductive technology (ART) procedures, such as in vitro fertilization (IVF), medications are more common for female patients.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. Among these, the United States is expected to dominate the market due to its high disease prevalence rates and funding for research. Such areas are underpinned by the aging population and lifestyle-related risks in market growth. Support from the government and healthcare systems driving market expansion as it leads in clinical trials is a pioneer in treating the disease with targeted therapies, and immunotherapies. Rising emphasis on early diagnosis and customized treatment options is driving the market.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Established in New Delhi in 1991, Mankind Pharma is one of India's top-notch pharmaceutical companies. Its product range includes Siphene (clomphene citrate) which is an ovulation inducer widely used for female infertility. The fertility market in India as everywhere else is ever-growing and Mankind Pharma with its vision of treatment made affordable, ensures access to the widest range for the widest population.
Pfizer, which was established in 1849 and has its headquarters in New York City is a leading global pharmaceutical company as well. Menopur (menotropins) is a common drug in the company portfolio and is used to induce ovulation in women undergoing fertility treatment in the infertility drugs market.
Novartis is headquartered in Basel, Switzerland, and was founded in 1996 as a pharmaceutical company specializing in specialty and generics. Infertility treatments from Novartis include hormone-based therapies to assist in ART procedures. The company provides a variety of patient solutions by delivering progressive infertility drugs around the world and creating patient-friendly approaches for use with fertility treatment.
Bayer was founded in 1863 and is based in Leverkusen, Germany. It is best known for Puregon (follitropin beta), which is an artificial regimen that produces ovulation induction. Bayer's stronghold in hormone therapies is a leading combatant in the market and has already been conducting rigorous research aimed at developing cutting-edge solutions for female infertility as well as male infertility.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Merck KGaA, Ferring Pharmaceuticals Inc., Thermo Fisher Scientific, Inc., THERAMEX HQ UK LIMITED, Teva Pharmaceuticals Industries Ltd., and Livzon Pharmaceutical Group Inc., among others.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Gender |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share